The accumulation of macrophages attenuates the effect of recombinant human endostatin on lung cancer.

ABSTRACT:

Background

Although anti-angiogenic therapy is widely applied clinically, its efficacy has been less than expected. Screening for regulatory factors and sensitive indicators to define the effectiveness of these drugs is required. Through a retrospective study of clinical data, we found that patients with a higher peripheral monocyte-to-lymphocyte ratio (MLR) obtained less benefit from recombinant human endostatin (rhES, Endostar^®), an anti-angiogenic drug, in lung cancer. Because MLR is positively correlated with macrophage count in tumors, this result suggests that macrophages may influence the effectiveness of rhES therapy in lung cancer.

Methods

Clinical data from 72 lung cancer patients treated with rhES were collected. Animal study, flow cytometry, immunofluo

SUBMITTER: Liu Y 

PROVIDER: S-EPMC5087788 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature